Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway

Brain Research
G H Baltuch, V W Yong


Previous work has demonstrated that glioma cells have very high protein kinase C (PKC) enzyme activity when compared to non-malignant glia, and that their PKC activity correlates with their proliferation rate. The purpose of this study was to determine whether the elevated PKC activity in glioma is secondary to an autonomously active PKC isoform implying oncogenic transformation, or whether this activity is driven by upstream ligand-receptor tyrosine kinase interactions. We treated established human glioma cell lines A172, U563 or U251 with either the highly selective PKC inhibitor CGP 41 251, or with genistein, a tyrosine kinase inhibitor. The proliferation rate and PKC activity of all the glioma lines was reduced by CGP 41 251; the IC50 values for inhibiting cell proliferation corresponded to the IC50v values for inhibition of PKC activity. Genistein also inhibited cell proliferation, with IC50 proliferation values approximating those for inhibition of tyrosine kinase activity in cell free protein extracts. Importantly, in genistein-treated cells, downstream PKC enzyme activity was dose dependently reduced such that the correlation coefficient for effects of genistein on proliferation rate and PKC activity was 0.92. These fin...Continue Reading


Apr 15, 1992·Biochemical and Biophysical Research Communications·D M GadboisE M Bradbury
Jan 25, 1991·Cell·L C CantleyS Soltoff
Aug 31, 1990·Biochemical and Biophysical Research Communications·J M HerbertJ P Maffrand
Jun 1, 1989·Trends in Pharmacological Sciences·U T Rüegg, G M Burgess
Mar 13, 1986·Biochemical and Biophysical Research Communications·T TamaokiF Tomita
Oct 1, 1994·Neurosurgery·W T CouldwellR E Law
Feb 1, 1994·Trends in Biochemical Sciences·L V Dekker, P J Parker
Jan 1, 1994·Annual Review of Neuroscience·C Tanaka, Y Nishizuka
May 1, 1993·Journal of Neuro-oncology·G H BaltuchV W Yong
Sep 1, 1993·Pharmacology & Therapeutics·A Basu
May 1, 1993·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·G BaltuchJ G Villemure
Apr 15, 1993·The Biochemical Journal·H Hug, T F Sarre

❮ Previous
Next ❯


Jan 13, 2001·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·K KötterJ Klein
Oct 3, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A B da RochaG Schwartsmann
May 23, 1998·Annual Review of Pharmacology and Toxicology·L G Costa
Jul 30, 2008·Journal of Neurochemistry·Johannes RiegerWolfgang Wick
Nov 3, 2004·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Andrew P Morokoff, Ulrike Novak
Feb 1, 2000·Toxicology and Applied Pharmacology·M WeiL G Costa
Dec 6, 1997·International Journal of Cancer. Journal International Du Cancer·E LevinR W Levin
Sep 9, 2006·The Journal of Pharmacology and Experimental Therapeutics·Esther P JaneIan F Pollack
Nov 11, 1998·General Pharmacology·A Gescher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.